Pembrolizumab in First-Line Treatment of Advanced-Stage Classical Hodgkin Lymphoma

Phase II Trial of Pembrolizumab in First-Line Treatment of Advanced-Stage Classical Hodgkin Lymphoma

The primary objective of this trial is to estimate efficacy of the novel regimen. The primary endpoint is the 1-year PFS rate after treatment with one dose of pembrolizumab followed by four to six cycles of chemo-immunotherapy with P-BrECADD, and PET-guided radiotherapy as per standard of care

Main Inclusion Criteria:

• age 18-60
• advanced stage classical Hodgkin Lymphoma
• no previous treatment for cHL

Main Exclusion Criteria:

• Nodular lymphocyte-predominant Hodgkin lymphoma or composite lymphoma
• Chemotherapy or radiotherapy in medical history
• Prior or concurrent disease that prevents treatment according to protocol